{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,22]],"date-time":"2026-11-22T04:05:04Z","timestamp":1795320304490,"version":"4.10.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21021"],"award-info":[{"award-number":["21021"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Although the painful and disabling features of early diffuse cutaneous SSc (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not they should be prescribed is therefore highly contentious. Our aim was to examine safety and efficacy of moderate-dose prednisolone in early dcSSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRedSS set out as a Phase II, multicentre, double-blind randomized controlled trial, converted to open-label during the Covid-19 pandemic. Patients were randomized to receive either prednisolone (\u223c0.3\u2009mg\/kg) or matching placebo (or no treatment during open-label) for 6\u2009months. Co-primary endpoints were the HAQ Disability Index (HAQ-DI) and modified Rodnan skin score (mRSS) at 3\u2009months. Over 20 secondary endpoints included patient reported outcome measures reflecting pain, itch, fatigue, anxiety and depression, and helplessness. Target recruitment was 72 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five patients were randomized (17 prednisolone, 18 placebo\/control). The adjusted mean difference between treatment groups at 3\u2009months in HAQ-DI score was \u22120.10 (97.5% CI: \u22120.29, 0.10), P\u2009=\u20090.254, and in mRSS \u22123.90 (97.5% CI: \u22128.83, 1.03), P\u2009=\u20090.070, both favouring prednisolone but not significantly. Patients in the prednisolone group experienced significantly less pain (P\u2009=\u20090.027), anxiety (P\u2009=\u20090.018) and helplessness (P\u2009=\u20090.040) than control patients at 3\u2009months. There were no renal crises, but sample size was small.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PRedSS was terminated early primarily due to the Covid-19 pandemic, and so was underpowered. Therefore, interpretation must be cautious and results considered inconclusive, indicating the need for a further randomized trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT03708718.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead012","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:00:19Z","timestamp":1673524819000},"page":"3133-3138","source":"Crossref","is-referenced-by-count":16,"title":["A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)"],"prefix":"10.1093","volume":"62","author":[{"given":"Deborah J","family":"Griffiths-Jones","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Sylvestre","family":"Garcia","sequence":"additional","affiliation":[{"name":"Manchester Clinical Trials Unit, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W David","family":"Ryder","sequence":"additional","affiliation":[{"name":"Manchester Clinical Trials Unit, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-2364","authenticated-orcid":false,"given":"John D","family":"Pauling","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal United Hospitals Bath NHS Trust , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lanyon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ninewells Hospital and Medical School , Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Douglas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dudley Group NHSFT , Dudley, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Gunawardena","sequence":"additional","affiliation":[{"name":"Rheumatology Department, North Bristol NHS Trust, and Academic Rheumatology, University of Bristol , Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Akil","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Anderson","sequence":"additional","affiliation":[{"name":"Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster and Liverpool University Hospitals NHS Foundation Trust , Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre and Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Youssef","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aberdeen Royal Infirmary , Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Madhok","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, Glasgow Royal Infirmary , Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Arthurs","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya","family":"Buch","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester , Manchester, UK"},{"name":"NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Fligelstone","sequence":"additional","affiliation":[{"name":"Royal Free Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Zubair","sequence":"additional","affiliation":[{"name":"Research Governance and Integrity, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C","family":"Mason","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, Hammersmith Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, UCL Division of Medicine, Royal Free Campus , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-7926","authenticated-orcid":false,"given":"Ariane L","family":"Herrick","sequence":"additional","affiliation":[{"name":"NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester, UK"},{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"2023090115144761900_kead012-B1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need","volume":"18","author":"Herrick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2023090115144761900_kead012-B2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/rheumatology\/kex410","article-title":"Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study","volume":"57","author":"Peytrignet","year":"2018","journal-title":"Rheumatology"},{"key":"2023090115144761900_kead012-B3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kez299","article-title":"Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity","volume":"59","author":"Zheng","year":"2020","journal-title":"Rheumatology"},{"key":"2023090115144761900_kead012-B4","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology"},{"key":"2023090115144761900_kead012-B5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023090115144761900_kead012-B6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023090115144761900_kead012-B7","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"Van Laar","year":"2014","journal-title":"JAMA"},{"key":"2023090115144761900_kead012-B8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Eng J Med"},{"key":"2023090115144761900_kead012-B9","doi-asserted-by":"crossref","first-page":"102403","DOI":"10.1016\/j.autrev.2019.102403","article-title":"Is there today a place for corticosteroids in the treatment of scleroderma?","volume":"18","author":"Blagojevic","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2023090115144761900_kead012-B10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2023090115144761900_kead012-B11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","article-title":"Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls","volume":"51","author":"Guillevin","year":"2012","journal-title":"Rheumatology"},{"key":"2023090115144761900_kead012-B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.autrev.2017.02.012","article-title":"Towards developing criteria for scleroderma renal crisis: a scoping review","volume":"16","author":"Hoa","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2023090115144761900_kead012-B13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/2397198320957552","article-title":"Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS)","volume":"6","author":"Herrick","year":"2021","journal-title":"J Scleroderma Rel Disord"},{"key":"2023090115144761900_kead012-B14","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2023090115144761900_kead012-B15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardisation of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"Suppl 5","key":"2023090115144761900_kead012-B16","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/ken269","article-title":"Outcome measures in rheumatologic clinical trials and systemic sclerosis","volume":"47","author":"Furst","year":"2008","journal-title":"Rheumatology"},{"key":"2023090115144761900_kead012-B17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"key":"2023090115144761900_kead012-B18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimally clinically important differences for the modified Rodnan skin score: result from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023090115144761900_kead012-B19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2020-219775","article-title":"PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic","volume":"80","author":"Spierings","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead012\/48945317\/kead012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3133\/51329163\/kead012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3133\/51329163\/kead012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:38:22Z","timestamp":1693568302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/9\/3133\/6986975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,13]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead012","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,1,13]]}}}